Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

InsmedINSM stock hit a record high Tuesday after the Food and Drug Administration approved its drug, brensocatib, for ...

Q2 2025 Management View William H. Lewis, President, CEO & Chairman, highlighted, "Insmed is now three for three, all three ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.